Here's Why Zoetis (ZTS) Gained But Lagged the Market Today
Zoetis (ZTS) closed the most recent trading day at $164.84, moving +0.81% from the previous trading session.
Here's Why Zoetis (ZTS) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The animal health industry is resilient, Zoetis CEO
Zoetis CEO Kristin Peck unpacks pet owners' concerns in caring for their beloved animals on 'The Claman Countdown.'
Zoetis (ZTS) Up 1% Since Last Earnings Report: Can It Continue?
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?
Zoetis: Healing Paws, Growing Profits
Zoetis is active in multiple segments that are all expected to grow at a CAGR of 4% or more. The company has growing revenues, a strong balance sheet, a high FCF margin, and no major maturities. Librela, Solensia and Simparica Trio will drive the stock going forward.
Why Zoetis (ZTS) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zoetis Inc. (ZTS) Management presents at Jefferies London Healthcare Conference (Transcript)
Zoetis Inc. (NYSE:ZTS ) Jefferies London Healthcare Conference November 20, 2024 10:00 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo Thank you for taking the time to join us this afternoon. We're very excited to have Zoetis for our next presentation.
Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy
Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO, outperforming the S&P 500. The company benefits from increasing global pet ownership and spending, making its revenues less susceptible to economic downturns. Zoetis boasts a strong competitive moat with a diverse product portfolio, significant patent protection, and consistent R&D investment.
Zoetis: The Major Player in the $500B Pet Market You May Not Have Heard Of
The pet industry is growing fast and could reach a global market size of half a trillion dollars by 2032. This episode looks at why people bought more pets during COVID, the trend of treating pets like family, and key public companies in the pet space, like Zoetis. Zoetis Executive Vice President and CFO Wetteny Joseph shares how the company works in both companion and production animal health. He talks about their top products, research investments, use of AI, and strong financial results. Despite challenges, Zoetis keeps pushing for innovation and profit in animal health.
1 Magnificent S&P 500 Dividend Stock Down 12% to Buy After Its Recent Pullback
Zoetis looks like a classic example of a premium business trading at a fair price following its recent dip.
Zoetis Q3: Strong Osteoarthritis Pain Franchise
I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures. The Company's osteoarthritis drugs, LIBRELA and SOLENSIA, delivered 97% operational revenue growth, with LIBRELA poised to become a $1 billion franchise. Zoetis projects 10–11% operational revenue growth and 13.5–14.5% adjusted net income growth for FY24, despite minor headwinds from China.
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.
